Abstract
Management of dopamine agonist (DA)–resistant prolactinomas that are not responding to second- and third-line treatments is challenging and necessitates alternative medical therapy. The presence of estrogen receptors on pituitary tumors accompanied by the variable behavior of pituitary tumors in the presence of estrogen prompted the study of the role of antiestrogen in the treatment of DA-resistant prolactinomas. The purpose of this paper is to provide a systematic review of the role of tamoxifen in the treatment of prolactin-secreting adenomas resistant to dopamine agonists.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
